全文获取类型
收费全文 | 20773篇 |
免费 | 1421篇 |
国内免费 | 85篇 |
专业分类
耳鼻咽喉 | 211篇 |
儿科学 | 572篇 |
妇产科学 | 493篇 |
基础医学 | 2495篇 |
口腔科学 | 437篇 |
临床医学 | 2251篇 |
内科学 | 4137篇 |
皮肤病学 | 189篇 |
神经病学 | 2127篇 |
特种医学 | 679篇 |
外国民族医学 | 3篇 |
外科学 | 3360篇 |
综合类 | 265篇 |
一般理论 | 24篇 |
预防医学 | 1669篇 |
眼科学 | 487篇 |
药学 | 1556篇 |
中国医学 | 15篇 |
肿瘤学 | 1309篇 |
出版年
2023年 | 89篇 |
2022年 | 177篇 |
2021年 | 354篇 |
2020年 | 229篇 |
2019年 | 374篇 |
2018年 | 434篇 |
2017年 | 306篇 |
2016年 | 347篇 |
2015年 | 426篇 |
2014年 | 601篇 |
2013年 | 898篇 |
2012年 | 1397篇 |
2011年 | 1472篇 |
2010年 | 839篇 |
2009年 | 689篇 |
2008年 | 1397篇 |
2007年 | 1583篇 |
2006年 | 1357篇 |
2005年 | 1367篇 |
2004年 | 1413篇 |
2003年 | 1232篇 |
2002年 | 1219篇 |
2001年 | 224篇 |
2000年 | 191篇 |
1999年 | 238篇 |
1998年 | 285篇 |
1997年 | 243篇 |
1996年 | 188篇 |
1995年 | 154篇 |
1994年 | 147篇 |
1993年 | 146篇 |
1992年 | 155篇 |
1991年 | 132篇 |
1990年 | 116篇 |
1989年 | 103篇 |
1988年 | 87篇 |
1987年 | 104篇 |
1986年 | 95篇 |
1985年 | 78篇 |
1984年 | 89篇 |
1983年 | 104篇 |
1982年 | 97篇 |
1981年 | 104篇 |
1980年 | 83篇 |
1979年 | 68篇 |
1978年 | 72篇 |
1977年 | 60篇 |
1976年 | 70篇 |
1975年 | 69篇 |
1974年 | 58篇 |
排序方式: 共有10000条查询结果,搜索用时 14 毫秒
991.
Data on passive lengthening and active shortening from electrical stimulation to give a total functional excursion are presented. Length-tension characteristics of certain muscles used for transfer are given. Electrical stimulation of the newly transferred tendon gives useful information that is reproducible. This new knowledge obtained at operation is an important adjunct to the traditional techniques and provides helpful information in performing better procedures. 相似文献
992.
993.
994.
Retroviral insertions that activate proto-oncogenes are a primary cause of tumors in certain strains of mice. The AKXD recombinant inbred mice are predisposed to a variety of leukemias and lymphomas as a result of viral integration. One common insertion site, the ecotropic viral insertion site 3 (Evi3), has been implicated in most B-cell tumors in the AKXD-27 strain. The Evi3 gene encodes a zinc-finger protein with sequence similarity to the Early B-cell Factor-Associated Zinc-finger gene (EBFAZ). We show that the Evi3 gene is overexpressed in several tumors with viral insertions at Evi3, which results in the upregulation of Early B-cell Factor (EBF)-target gene expression, suggesting that Evi3 modulates EBF activity. Reconstitution of primary leukemia cells showed that these tumors express high densities of the B-cell surface proteins CD19 and CD38, which are EBF targets. Using a transactivation assay, we show that the terminal six zinc-fingers of Evi3 are required for modification of EBF activity. This is the first evidence that Evi3 expression in tumors alters the level of EBF target genes, and the first characterization of the Evi3 protein domains required for modulation of EBF activity. Further, these data imply that Evi3 misexpression initiates tumorigenesis by perturbing B-cell development via an interaction with EBF. 相似文献
995.
Kellie SJ Chaku J Lockwood LR O'Regan P Waters KD Wong CK;Australian New Zealand Children's Haematology Oncology Group 《European journal of cancer (Oxford, England : 1990)》2005,41(11):1588-1596
High-dose methotrexate (HDMTX) is used increasingly to treat children with central nervous system (CNS) tumours. Although the neuro-imaging features of leukoencephalopathy associated with systemic or intrathecal methotrexate administered after cranial radiation have been well described, the extent to which the sequencing of HDMTX prior to cranial radiation in infants and children predisposes to late neuroradiological features of leukoencephalopathy is unknown. This report describes the National Cancer Institute (NCI) toxicity grade of leukoencephalopathy based on magnetic resonance imaging (MRI) findings in all patients who survived 4 or more years after treatment on an earlier phase II study. These patients, with newly diagnosed CNS embryonal tumours, were in the age range 3.5-14.2 years (median 6.9 years) at diagnosis, and received four courses of pre-irradiation combination chemotherapy, including HDMTX 8 g/m(2). Following completion of the 'up-front' phase II study, all patients received conventionally fractionated whole brain doses of 36-50.4 Gy. The radiation dose and treatment volumes were determined individually according to the primary tumour location and results of extent of disease evaluations. The most recent MRI brain scans, obtained 4.0-10.5 years (median 6.5 years) after radiation therapy and comprising a minimum of T1, T1 following gadolinium and T2 sequences, were reviewed centrally to assess the neuroradiological grade of leukoencephalopathy, based on the NCI Common Terminology Criteria for Adverse Events, v3.0. Grade I changes (mild increase in subarachnoid space, and/or mild ventriculomegaly, and/or small/focal T2 hyperintensities) were evident in 8 of the 12 patients and grade II changes (moderate increase in subarachnoid space and/or moderate ventriculomegaly, and/or focal T2 hyperintensities extending to the centrum ovale) were found in the remaining 4. In conclusion, treatment with multiple courses of HDMTX prior to 36-50.4 Gy cranial radiation did not result in moderate to severe MRI features of leukoencephalopathy. Future studies in paediatric neuro-oncology patients, involving HDMTX combined with prospective neuropsychological evaluations appear justified. 相似文献
996.
Afshin Dowlati Kelly Robertson Tomas Radivoyevitch John Waas Nicholas P Ziats Paul Hartman Fadi W Abdul-Karim Jay K Wasman Jack Jesberger Jonathan Lewin Keith McCrae Percy Ivy Scot C Remick 《Clinical cancer research》2005,11(21):7938-7944
PURPOSE: To determine the biological modulatory dose of SU5416, we employed a novel trial design, where "dose de-escalation" was based on demonstrable biological changes observed at the maximum tolerated dose. If such an effect was shown, dose de-escalation to a predefined dose level would occur to determine if the lower dose exhibited the same amount of pharmacodynamic effect as the higher dose. EXPERIMENTAL DESIGN: Ten patients with advanced solid tumors were enrolled at each dose level. One of the following pharmacodynamic effects was considered significant: (a) a 35% decrease in microvessel density in sequential tumor biopsies and (b) a 35% decrease in blood flow within tumor as assessed by dynamic contrast-enhanced magnetic resonance imaging. In addition, soluble E-selectin, soluble intercellular adhesion molecule, soluble vascular cell adhesion molecule, and plasma vascular endothelial growth factor were measured sequentially. RESULTS: Nineteen patients were enrolled. Sequential tumor biopsies in all evaluable patients showed an increase in microvessel density. Only one patient met the intended pharmacodynamic end point of >35% reduction in blood flow. There was a significant increase in both soluble E-selectin and soluble intercellular adhesion molecule levels pretreatment versus levels at the time of removal of patients from study (P = 0.04 and P = 0.0007, respectively). Levels of serum fibrinogen rose with therapy. There was a trend toward increase in plasma vascular endothelial growth factor levels. CONCLUSION: SU5416 does not result in decreased blood flow in tumors or a decrease in microvessel density. This corresponds to the lack of clinical activity seen with this agent. Our clinical trial design termed dose de-escalation is a novel approach to determine the in vivo biological effects of targeted therapies in cancer patients. 相似文献
997.
Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo 总被引:4,自引:0,他引:4
Shi Y Liu X Han EK Guan R Shoemaker AR Oleksijew A Woods KW Fisher JP Klinghofer V Lasko L McGonigal T Li Q Rosenberg SH Giranda VL Luo Y 《Neoplasia (New York, N.Y.)》2005,7(11):992-1000
Akt is a serine/threonine kinase that transduces survival signals from survival/growth factors. Deregulation and signal imbalance in cancer cells make them prone to apoptosis. Upregulation or activation of Akt to aid the survival of cancer cells is a common theme in human malignancies. We have developed small-molecule Akt inhibitors that are potent and specific. These Akt inhibitors can inhibit Akt activity and block phosphorylation by Akt on multiple downstream targets in cells. Synergy in apoptosis induction was observed when Akt inhibitors were combined with doxorubicin or camptothecin. Akt inhibitor-induced enhancement of topoisomerase inhibitor cytotoxicity was also evident in long-term cell survival assay. Synergy with paclitaxel in apoptosis induction was evident in cells pretreated with paclitaxel, and enhancement of tumor delay by paclitaxel was demonstrated through cotreatment with Akt inhibitor Compound A (A-443654). Combination with other classes of chemotherapeutic agents did not yield any enhancement of cytotoxicity. These findings provide important guidance in selecting appropriate classes of chemotherapeutic agents for combination with Akt inhibitors in cancer treatment. 相似文献
998.
Inflammation, COX-2 inhibitors, and cancer 总被引:2,自引:0,他引:2
Block KI 《Integrative cancer therapies》2005,4(1):3-4
999.
1000.